Brief: Bergenbio: Data From Phase I/II Bemcentinib/Erlotinib Combination Trial

Oncoinvent ASA

04/06/2021 14:46

June 4 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO PRESENTS DATA FROM PHASE I/II
BEMCENTINIB/ERLOTINIB
COMBINATION TRIAL IN NSCLC AT ASCO MEETING
    * DATA FROM STUDY FOUND THAT BEMCENTINIB IN COMBINATION WITH
ERLOTINIB WAS WELL TOLERATED OVER EXTENDED PERIODS OF TIME, WITH
LONGEST ONGOING PATIENTS HAVING BEEN DOSED FOR OVER 46 MONTHS
    * COMBINATION LED TO DISEASE STABILISATION AND DURABLE
TUMOUR
RESPONSES IN A PROPORTION OF PATIENTS WHO HAD PREVIOUSLY
PROGRESSED ON EGFR TARGETED THERAPY AND WHO WERE NEGATIVE FOR
T790M RESISTANCE MUTATION

Source text for Eikon:  ID:nWkr5rhm7W 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))